4D Molecular Therapeutics (ticker: FDMT) reported positive 52-week and 60-week results from its SPECTRA clinical trial evaluating 4D-150 for diabetic macular edema (DME). The data demonstrated durable visual gains, sustained reduction in central subfield thickness (CST), and a roughly 78% decrease in injection frequency compared to aflibercept, with no safety concerns noted. The company also reached an agreement with the European Medicines Agency (EMA) on a registrational pathway for 4D-150 in DME. Following the announcement, FDMT shares surged by as much as 34.7% in pre-market trading. Separately, Genentech's Susvimo treatment for wet age-related macular degeneration (AMD) maintained stable vision over five years with only two refills per year, underscoring advancements in long-term ocular therapies.